10 analysts have shared their evaluations of Immunocore Hldgs IMCR during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 3 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 2 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $81.4, a high estimate of $92.00, and a low estimate of $63.00. Observing a 12.12% increase, the current average has risen from the previous average price target of $72.60.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive Immunocore Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jonathan Chang | Leerink Partners | Announces | Outperform | $74.00 | - |
| Michael Schmidt | Guggenheim | Maintains | Buy | $92.00 | - |
| Gil Blum | Needham | Maintains | Buy | $81.00 | - |
| Jessica Fye | JP Morgan | Raises | Overweight | $70.00 | $60.00 |
| Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $90.00 | - |
| Graig Suvannavejh | Mizuho | Raises | Buy | $90.00 | $86.00 |
| Justin Kim | Oppenheimer | Raises | Outperform | $87.00 | $85.00 |
| Bill Maughan | Canaccord Genuity | Raises | Hold | $63.00 | $60.00 |
| Gil Blum | Needham | Maintains | Buy | $81.00 | - |
| Graig Suvannavejh | Mizuho | Raises | Buy | $86.00 | $72.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Immunocore Hldgs. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Immunocore Hldgs compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Immunocore Hldgs's stock. This examination reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Immunocore Hldgs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Immunocore Hldgs analyst ratings.
Get to Know Immunocore Hldgs Better
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
Immunocore Hldgs: A Financial Overview
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Immunocore Hldgs displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 34.25%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Immunocore Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -25.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -8.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Immunocore Hldgs's ROA stands out, surpassing industry averages. With an impressive ROA of -4.98%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Immunocore Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.23, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
How Are Analyst Ratings Determined?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
